206 related articles for article (PubMed ID: 36351995)
1. Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer.
Hrudka J; Matěj R; Nikov A; Tomyak I; Fišerová H; Jelínková K; Waldauf P
Sci Rep; 2022 Nov; 12(1):19152. PubMed ID: 36351995
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 7 expression as a predictor of an unfavorable prognosis in colorectal carcinoma.
Hrudka J; Fišerová H; Jelínková K; Matěj R; Waldauf P
Sci Rep; 2021 Sep; 11(1):17863. PubMed ID: 34504224
[TBL] [Abstract][Full Text] [Related]
3. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
6. Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall.
Neri G; Arpa G; Guerini C; Grillo F; Lenti MV; Giuffrida P; Furlan D; Sessa F; Quaquarini E; Viglio A; Ubezio C; Pasini A; Ferrero S; Sampietro G; Ardizzone S; Latella G; Mescoli C; Rugge M; Zingone F; Barresi V; Ciccocioppo R; Pedrazzoli P; Corazza GR; Luinetti O; Solcia E; Paulli M; Di Sabatino A; Vanoli A
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228145
[TBL] [Abstract][Full Text] [Related]
7. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.
Eberhard J; Gaber A; Wangefjord S; Nodin B; Uhlén M; Ericson Lindquist K; Jirström K
Br J Cancer; 2012 Feb; 106(5):931-8. PubMed ID: 22333599
[TBL] [Abstract][Full Text] [Related]
8. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
Nodin B; Johannesson H; Wangefjord S; O'Connor DP; Lindquist KE; Uhlén M; Jirström K; Eberhard J
Diagn Pathol; 2012 Aug; 7():115. PubMed ID: 22935204
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
Lyn J; Wang Y; Wang F; Shen M; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
[TBL] [Abstract][Full Text] [Related]
10. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
Li J; Zeng Q; Lin J; Huang H; Chen L
Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
12. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
[TBL] [Abstract][Full Text] [Related]
13. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
14. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma.
Al-Jussani GN; Alsughayer A; Yousuf MS; Mullahuwash Y; Dabbagh T; Sughayer MA
Int J Biol Markers; 2022 Sep; 37(3):322-327. PubMed ID: 35635229
[TBL] [Abstract][Full Text] [Related]
18. The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.
Yomoda T; Sudo T; Kawahara A; Shigaki T; Shimomura S; Tajiri K; Nagasu S; Fujita F; Kinugasa T; Akagi Y
Ann Surg Oncol; 2019 Feb; 26(2):415-424. PubMed ID: 30569297
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]